I subsequently asked for more information on the board deliberations, with a response as follows:Detailed Breakdown of Board Meetings and Deliberations
Strategic Considerations
Assessment of Standalone Prospects:
- The Board analyzed Morphic's future as an independent company. This included evaluating the company's financial projections, research and development pipeline, and market positioning.
- Consideration of risks and challenges associated with remaining independent, such as market volatility, funding needs, and competitive pressures.
Exploration of Strategic Alternatives:
- The Board considered various strategic alternatives to maximize shareholder value. These included potential partnerships, alliances, or other forms of transactions beyond an outright sale.
- Evaluation of potential synergies with other companies, industry trends, and the broader market landscape to determine the best path forward.
Assessment of Acquisition Interest:
- The Board reviewed interest from other potential acquirers. While Lilly's offer was the primary focus, the Board remained open to exploring offers from other interested parties.
- Discussions around the feasibility and desirability of pursuing alternative acquisition proposals, and the potential for a competitive bidding process.
Financial Advisor Involvement
Selection of Financial Advisor:
- The Board engaged a financial advisor to provide expert analysis and advice on the potential transaction with Lilly.
- The financial advisor's role was to offer an independent assessment of the offer, provide financial analyses, and explore other strategic alternatives.
Financial Analyses and Valuation:
- The financial advisor conducted comprehensive financial analyses, including discounted cash flow analyses, comparable company analyses, and precedent transaction analyses.
- These analyses helped the Board understand the intrinsic value of Morphic and assess whether Lilly's offer was financially attractive.
Evaluation of Other Strategic Alternatives:
- The financial advisor assisted in evaluating the feasibility and potential value of other strategic alternatives, including remaining independent or pursuing other transactions.
- This included modeling different scenarios and assessing the potential financial outcomes for shareholders under each alternative.
Offer Evaluation
Multiple Board Meetings:
- The Board held several meetings to discuss and evaluate the potential transaction with Lilly.
- These meetings involved detailed presentations from the financial advisor, legal counsel, and management team.
Consideration of Financial and Market Factors:
- The Board reviewed financial analyses provided by the financial advisor, including the impact of the offer on shareholder value.
- Consideration of market conditions, including the competitive landscape, industry trends, and economic factors that could influence the company's future prospects.
Risk Assessment:
- The Board assessed the risks associated with both accepting the offer and continuing as an independent company.
- This included evaluating operational risks, financial risks, and market risks, as well as the potential impact on the company's strategic objectives.
Comprehensive Review and Deliberation:
- The Board engaged in thorough discussions and deliberations, weighing the benefits and drawbacks of the offer.
- Consideration of the timing and certainty of the transaction, including regulatory approval processes and the likelihood of closing the deal.
Final Decision:
- After careful consideration of all factors, the Board concluded that the offer from Lilly was in the best interests of Morphic and its shareholders.
- The Board unanimously recommended that shareholders accept the offer and tender their shares.
This detailed breakdown provides a comprehensive understanding of the Board's meetings and deliberations, strategic considerations, financial advisor involvement, and the evaluation of Lilly's offer.
- Forums
- ASX - By Stock
- NEU
- Share Price
Share Price, page-10937
-
- There are more pages in this discussion • 520 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.52 |
Change
0.310(2.04%) |
Mkt cap ! $1.983B |
Open | High | Low | Value | Volume |
$15.19 | $15.62 | $15.11 | $8.655M | 558.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 440 | $15.48 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.54 | 752 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 440 | 15.480 |
1 | 175 | 15.350 |
1 | 708 | 15.210 |
3 | 6677 | 15.200 |
1 | 330 | 15.150 |
Price($) | Vol. | No. |
---|---|---|
15.610 | 5000 | 1 |
15.700 | 250 | 1 |
15.900 | 2000 | 1 |
15.980 | 26038 | 1 |
16.000 | 20 | 1 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online